Medical AI startup Aidoc raises $150M from Goldman Sachs and Nvidia, eyes IPO within five years

Aidoc Secures Major Funding Round to Advance Medical AI Platform

Aidoc has closed a $150 million funding round led by Goldman Sachs Alternatives' growth equity division, marking a significant milestone for the medical AI company as it prepares for a potential public offering 1

1

. The Goldman Sachs-led funding attracted participation from Nvidia's NVentures, General Catalyst, and SoftBank Investment Advisors, bringing Aidoc's total capital raised to $520 million 1

1

2

2

. While the company declined to disclose its valuation, CEO Elad Walach indicated that Aidoc aims to IPO within three to five years 1

1

.

AI in Radiology Reaches Scale with Advanced Foundation Model

The company's aiOS platform leverages a proprietary foundation model called the Clinical AI Reasoning Engine (CARE) that represents a departure from traditional single-purpose medical AI systems 2

2

. Unlike clinical-grade AI models historically trained to process only one type of medical data, CARE can analyze medical imaging including CT scans and X-rays, electronic health records, patient vitals, and lab results 2

2

. The platform's AI capabilities enable it to read and flag incidental findings on CT scans, supporting critical use cases such as emergency department triage and identifying abnormalities on abdominal scans, including liver and spleen injuries and appendicitis 1

1

.

FDA Clearances Validate Clinical Accuracy and Diagnostics Performance

Aidoc has secured 31 FDA clearances for various use cases ranging from emergency department triage to detecting conditions on abdominal scans 1

1

. In January, the U.S. Food and Drug Administration cleared CARE for diagnostic tasks across 11 disease indicators, adding to three other indicators previously approved 2

2

. The company reports that CARE achieves specificity of up to 99.7%, corresponding to less than 1% chance of false positives—approximately an order of magnitude better than some competing models 2

2

. The algorithm's mean specificity across the 11 FDA-approved disease indicators stands at 98% 2

2

.

Funding Targets Regulatory Navigation and Model Development

Proceeds from the funding round will help Aidoc navigate the notoriously expensive regulatory approval process and invest in building a large, comprehensive AI model, according to Walach 1

1

. The dually headquartered company in Israel and New York has built a foundation model that allows customers to deploy tools from third-party companies, expanding its platform's flexibility 1

1

. Aidoc's platform is currently installed in nearly 2,000 hospitals worldwide, where medical teams use it to process data about more than 60 million patients per year 2

2

.

Competition Intensifies in Radiology Services Market

Aidoc faces competition from both incumbents and startups as dealmaking in the medical imaging space continues to accelerate. GE HealthCare has made multiple acquisitions since spinning off from GE, completing a $2.3 billion acquisition of Intelerad last month 1

1

. Siemens Healthineers launched its own radiology services suite designed to assist providers with scheduling, reporting, and image generation last year 1

1

. RadAI raised a $60 million Series C last month led by Transformation Capital, achieving a valuation of $525 million 1

1

. The competitive landscape suggests that AI-powered diagnostics will continue attracting significant investment as healthcare systems seek to improve efficiency and patient outcomes.